Sale

Liquid Biopsy Market

Global Liquid Biopsy Market Size, Share, Trends, Analysis: By Sample: Blood Sample, Others; By Biomarker: Circulating Tumor Cells (CTCs), Circulating Nucleic Acids, Exosomes/ Microvesicles, Circulating Proteins; By Technology; By Application; By End-use; By Clinical Application; By Product; Regional Analysis; Supplier Landscape; 2024-2032

Global Liquid Biopsy Market Outlook

The global liquid biopsy market size was valued at USD 2269.81 billion in 2023, driven by the rising incidence of cancer cases across the globe. The market is expected to grow at a CAGR of 22.0% during the forecast period of 2024-2032, with the values likely to rise from USD 2769.17 billion in 2024 to USD 13591.48 billion by 2032.

 

Global Liquid Biopsy Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Liquid Biopsy Market Overview

Liquid biopsy is a blood test used to detect cancerous tumors floating in the blood stream. It can help identify circulating tumor cells (CTCs) as well as circulating tumor DNA (ctDNA). It is a relatively newer technique used to monitor tumor recurrence and study the treatment response with precision. It is highly preferred as it facilitates early detection of cancer as compared to other screening tools such as MRI or other imaging tests.

 

The overall market growth is driven by the growing prevalence of cancer, increasing research and development activities and technological advancements as well as rising investments in healthcare companies to develop innovative and improved solutions for patients.

 

Rising Incidence of Cancer Cases

The liquid biopsy market demand can be attributed to rising incidence of cancer. In 2023, approximately 2 million people are expected to be diagnosed by cancer in the United States alone. Breast cancer is the most diagnosed cancer estimated to affect 297,790 women and 2,800 men. While prostate cancer is the second most common cancer type with 288,300 expected cases. Out of the 2 million people diagnosed, around 609,820 mortalities are associated with the disease. Lung and bronchus cancer is projected to be a leading cause of deaths, responsible for 127,070 deaths, followed by colorectal cancer (52,550 deaths) and pancreatic cancer (50,550 deaths).

 

Advancements in Technology for Improved Specificity of Treatment

Early diagnosis of cancer helps in providing improved treatment solutions to patients. Simultaneously, it is critical to determine the pattern for tumor progression as well. Liquid biopsy has emerged as an effective technique to accomplish such procedures. There has been significant emphasis on improving the existing solutions and bringing in advanced technologies to boost the liquid biopsy market share globally. In February 2023, BCRF researchers developed HDSCA3.0 , a third-generation liquid biopsy technology. This new technology uses five different biomarkers to detect and distinguish rare circulating cells at a high resolution. When used along with other screening techniques, it has shown promising results to help the healthcare practitioners make informed decisions.

 

Growing Research Activities for Advanced Testing

The preference for liquid biopsy has seen a significant upswing owing to its better accuracy and less invasive nature as compared to traditional methods such as tissue biopsy. Microfluidic  based lab-on-a-chip technology is the latest addition to the liquid biopsy market. These chips have been successfully applied in cancer diagnosis and monitoring. To support the latest technological advancements, subsequent changes are being made to the hardware equipment as well. The rising trend of point of care diagnostics based on cell-based assays along with whole blood cell counting is one of the major aspects of liquid biopsy market growth.

 

Increasing Investments from Emerging Healthcare Companies

In March 2023, a new biotechnology company called Droplet  Biosciences announced a USD 8 million seed investment to develop a novel platform to analyze lymph fluid samples from patients with cancer. The tests are focused on head and neck cancer, however, the company aims at expanding the technology application to other parts of the body. The tests developed by the company are more sensitive when compared to others. In addition, they are conducted shortly after the surgery which allows the results to be returned in time for informed alternative therapy decisions. The rising fundings from budding organizations is one of the significant liquid biopsy market trends.

 

In April 2023, Foresight  Diagnostics, Inc, a pioneering developer of ultrasensitive cancer detection tests, received USD 58.75 million series B funding from Foresite Capital, in participation with Civilization Ventures, Stanford University, Bluebird Ventures, Pear Ventures, Agent Capital, and The University of Colorado Healthcare Innovation Fund. The funding was intended to be applied in the clinical development and commercialization of PhasED-Seq™, the company’s MRD (minimal residue disease) platform. It aims at leveraging the sequencing of phased variants for detecting circulating tumor DNA (ctDNA) in the bloodstream.

 

Global Liquid Biopsy Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Liquid Biopsy Market Segmentation

Market Breakup by Sample

  • Blood Sample
  • Others

 

Market Breakup by Biomarker

  • Circulating Tumor Cells (CTCs)
  • Circulating Nucleic Acids
  • Exosomes/ Microvesicles
  • Circulating Proteins

 

Market Breakup by Technology

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)

 

Market Breakup by Application

  • Cancer
  • Reproductive Health
  • Organ Transplantation
  • Infectious Diseases Testing
  • Others

 

Market Breakup by End-user

  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others

 

Market Breakup by Clinical Application

  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others

 

Market Breakup by Product

  • Instruments
  • Consumables Kits and Reagents
  • Software and Services

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin Americ
  • Middle East and Africa

 

Global Liquid Biopsy Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Liquid Biopsy Market Regional Analysis

North America, particularly the United States, is projected to lead the liquid biopsy market during the forecast period. The presence of robust healthcare and research and development infrastructure fosters growth in the region. The increasing product launches, along with mergers and acquisitions in prominent MedTech companies, are also contributing to the liquid biopsy market share. In May 2023, Lucence Health Inc.  launched LucenceINSIGHT™, its leading ctDNA-based liquid biopsy test screening technique in the United States headquarters.

 

Europe is another major market for liquid biopsy with various start-ups and companies coming into mainstream and developing their own diagnostic platforms. In February 2023, a Scotland-based startup called Dxcover  raised USD 11.9 million in series A and grant financing to develop its own liquid biopsy technology platform aimed at detecting early-stage cancers, constituting colorectal and brain cancers. The organization plans to use infrared spectroscopy and artificial intelligence algorithms to analyze patient blood samples and detect the presence or absence of the tumor.

 

Global Liquid Biopsy Market: Competitor Landscape

In October 2023, Precede Biosciences  launched a liquid biopsy platform in combination to their existing genome-wide platform which explores gene enhancers, promotors, and DNA methylome from a single millilitre (1mL) of plasma. Genomic liquid biopsy have helped in cancer care by offering somatic mutations. The new platform by the company interprets gene levels and pathway level biology genome-wide directly, with the help of 1 mL of plasma. The trend of automation and adoption of latest technologies has been a significant trend being adapted by several companies.

 

The key features of the liquid biopsy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • ANGLE plc
  • Oncimmune Holdings PLC
  • Guardant Health
  • Myriad Genetics, Inc.
  • Biocept, Inc.
  • Lucence Health Inc.
  • Freenome Holdings, Inc.
  • F.Hoffmann La Roche Ltd.
  • QIAGEN
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Exact Sciences Corporation
  • Bio-Rad Laboratories, Inc.
  • Menarini Silicon Biosystems S.p.A.
  • Epigenomics AG

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Sample
  • Biomarker
  • Technology
  • Application
  • End-use
  • Clinical Application
  • Product
  • Region
Breakup by Sample
  • Blood Sample
  • Others
Breakup by Biomarker
  • Circulating Tumor Cells (CTCs)
  • Circulating Nucleic Acids
  • Exosomes/ Microvesicles
  • Circulating Proteins
Breakup by Technology
  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)
Breakup by Application
  • Cancer 
  • Reproductive Health
  • Organ Transplantation
  • Infectious Diseases Testing
  • Others
Breakup by End-use
  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others
Breakup by Clinical Application
  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others
Breakup by Product
  • Instruments
  • Consumables Kits and Reagents
  • Software and Services
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • ANGLE plc
  • Oncimmune Holdings PLC
  • Guardant Health
  • Myriad Genetics, Inc.
  • Biocept, Inc.
  • Lucence Health Inc.
  • Freenome Holdings, Inc.
  • F.Hoffmann La Roche Ltd.
  • QIAGEN
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Exact Sciences Corporation
  • Bio-Rad Laboratories, Inc.
  • Menarini Silicon Biosystems S.p.A.
  • Epigenomics AG

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface 
    1.1    Objectives of the Study 
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology 
2    Executive Summary 
3    Global Liquid Biopsy Market Overview
 
    3.1    Global Liquid Biopsy Market Historical Value (2017-2023)  
    3.2    Global Liquid Biopsy Market Forecast Value (2024-2032) 
4    Global Liquid Biopsy Market Landscape 
    4.1    Global Liquid Biopsy Developers Landscape 
        4.1.1    Analysis by Year of Establishment 
        4.1.2    Analysis by Company Size 
        4.1.3    Analysis by Region 
    4.2    Global Liquid Biopsy Product Landscape 
        4.2.1    Analysis by Sample 
        4.2.2    Analysis by Biomarker 
        4.2.3    Analysis by Technology 
        4.2.4    Analysis by Application 
        4.2.5    Analysis by End-use 
        4.2.6    Analysis by Clinical Application
        4.2.7    Analysis by Product 
5    Global Liquid Biopsy Market Dynamics 
    5.1    Market Drivers and Constraints 
    5.2    SWOT Analysis 
    5.3    Porter’s Five Forces Model  
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators 
    5.6    Industry Events, Initiatives, and Trends
    5.7    Value Chain Analysis 
6    Global Liquid Biopsy Market Segmentation  
    6.1    Global Liquid Biopsy Market by Sample                                                                                
        6.1.1    Market Overview 
        6.1.2    Blood Sample
        6.1.3    Others
    6.2    Global Liquid Biopsy Market by Biomarker
        6.2.1    Market Overview 
        6.2.2    Circulating Tumor Cells (CTCs)
        6.2.3    Circulating Nucleic Acids
        6.2.4    Exosomes/ Microvesicles
        6.2.5    Circulating Proteins
    6.3    Global Liquid Biopsy Market by Technology
        6.3.1    Market Overview 
        6.3.2    Multi-gene-parallel Analysis (NGS)
        6.3.3    Single Gene Analysis (PCR Microarrays)
    6.4    Global Liquid Biopsy Market by Application
        6.4.1    Market Overview 
        6.4.2    Cancer 
        6.4.3    Reproductive Health
        6.4.4    Organ Transplantation
        6.4.5    Infectious Diseases Testing
        6.4.6    Others
    6.5    Global Liquid Biopsy Market by End-use                                                                               
        6.5.1    Market Overview 
        6.5.2    Hospitals and Laboratories
        6.5.3    Specialty Clinics
        6.5.4    Academic and Research Centers
        6.5.5    Others
    6.6    Global Liquid Biopsy Market by Clinical Application
        6.6.1    Market Overview 
        6.6.2    Therapy Selection
        6.6.3    Treatment Monitoring
        6.6.4    Early Cancer Screening
        6.6.5    Recurrence Monitoring
        6.6.6    Others
    6.7    Global Liquid Biopsy Market by Product
        6.7.1    Market Overview 
        6.7.2    Instruments
        6.7.3    Consumables Kits and Reagents
        6.7.4    Software and Services
    6.8    Global Liquid Biopsy Market by Region 
        6.8.1    Market Overview 
        6.8.2    North America  
        6.8.3    Europe 
        6.8.4    Asia Pacific 
        6.8.5    Latin America 
        6.8.6    Middle East and Africa 
7    North America Liquid Biopsy Market 
        7.1    Market Share by Country 
        7.2    United States of America 
        7.3    Canada 
8    Europe Liquid Biopsy Market 
    8.1    Market Share by Country 
    8.2    United Kingdom 
    8.3    Germany 
    8.4    France 
    8.5    Italy 
    8.6    Others 
9    Asia Pacific Liquid Biopsy Market 
    9.1    Market Share by Country 
    9.2    China 
    9.3    Japan 
    9.4    India 
    9.5    ASEAN  
    9.6    Others 
10    Latin America Liquid Biopsy Market 
    10.1    Market Share by Country 
    10.2    Brazil 
    10.3    Argentina 
    10.4    Mexico 
    10.5    Others 
11    Middle East and Africa Liquid Biopsy Market 
    11.1    Market Share by Country 
    11.2    Saudi Arabia 
    11.3    United Arab Emirates 
    11.4    Nigeria 
    11.5    South Africa 
    11.6    Others 
12    Patent Analysis 
    12.1    Analysis by Type of Patent 
    12.2    Analysis by Publication year 
    12.3    Analysis by Issuing Authority 
    12.4    Analysis by Patent Age 
    12.5    Analysis by CPC Analysis 
    12.6    Analysis by Patent Valuation  
    12.7    Analysis by Key Players 
13    Grants Analysis 
    13.1    Analysis by Year 
    13.2    Analysis by Amount Awarded 
    13.3    Analysis by Issuing Authority 
    13.4    Analysis by Grant Application 
    13.5    Analysis by Funding Institute 
    13.6    Analysis by NIH Departments 
    13.7    Analysis by Recipient Organization  
14    Funding and Investment Analysis 
    14.1    Analysis by Funding Instances 
    14.2    Analysis by Type of Funding 
    14.3    Analysis by Funding Amount 
    14.4    Analysis by Leading Players 
    14.5    Analysis by Leading Investors 
    14.6    Analysis by Geography 
15    Partnership and Collaborations Analysis 
    15.1    Analysis by Partnership Instances 
    15.2    Analysis by Type of Partnership 
    15.3    Analysis by Leading Players 
    15.4    Analysis by Geography 
16    Regulatory Framework 
    16.1    Regulatory Overview 
    16.2    US FDA 
    16.3    EU EMA 
    16.4    INDIA CDSCO 
    16.5    JAPAN PMDA 
    16.6    Others 
17    Supplier Landscape 
    17.1    ANGLE plc
        17.1.1    Financial Analysis 
        17.1.2    Product Portfolio 
        17.1.3    Demographic Reach and Achievements 
        17.1.4    Mergers and Acquisitions 
        17.1.5    Certifications 
    17.2    Oncimmune Holdings PLC 
        17.2.1    Financial Analysis 
        17.2.2    Product Portfolio 
        17.2.3    Demographic Reach and Achievements 
        17.2.4    Mergers and Acquisitions 
        17.2.5    Certifications 
    17.3    Guardant Health 
        17.3.1    Financial Analysis 
        17.3.2    Product Portfolio 
        17.3.3    Demographic Reach and Achievements 
        17.3.4    Mergers and Acquisitions 
        17.3.5    Certifications 
    17.4    Myriad Genetics, Inc.  
        17.4.1    Financial Analysis 
        17.4.2    Product Portfolio 
        17.4.3    Demographic Reach and Achievements 
        17.4.4    Mergers and Acquisitions 
        17.4.5    Certifications 
    17.5    Biocept, Inc.
        17.5.1    Financial Analysis 
        17.5.2    Product Portfolio 
        17.5.3    Demographic Reach and Achievements 
        17.5.4    Mergers and Acquisitions 
        17.5.5    Certifications 
    17.6    Lucence Health Inc. 
        17.6.1    Financial Analysis 
        17.6.2    Product Portfolio 
        17.6.3    Demographic Reach and Achievements 
        17.6.4    Mergers and Acquisitions 
        17.6.5    Certifications 
    17.7    Freenome Holdings, Inc.
        17.7.1    Financial Analysis 
        17.7.2    Product Portfolio 
        17.7.3    Demographic Reach and Achievements 
        17.7.4    Mergers and Acquisitions 
        17.7.5    Certifications 
    17.8    F.Hoffmann La Roche Ltd. 
        17.8.1    Financial Analysis 
        17.8.2    Product Portfolio 
        17.8.3    Demographic Reach and Achievements 
        17.8.4    Mergers and Acquisitions 
        17.8.5    Certifications 
    17.9    QIAGEN
        17.9.1    Financial Analysis 
        17.9.2    Product Portfolio 
        17.9.3    Demographic Reach and Achievements 
        17.9.4    Mergers and Acquisitions 
        17.9.5    Certifications 
    17.10    Illumina, Inc. 
        17.10.1    Financial Analysis 
        17.10.2    Product Portfolio 
        17.10.3    Demographic Reach and Achievements 
        17.10.4    Mergers and Acquisitions 
        17.10.5    Certifications 
    17.11    Thermo Fisher Scientific, Inc.
        17.11.1    Financial Analysis 
        17.11.2    Product Portfolio 
        17.11.3    Demographic Reach and Achievements 
        17.11.4    Mergers and Acquisitions 
        17.11.5    Certifications
    17.12    Exact Sciences Corporation 
        17.12.1    Financial Analysis 
        17.12.2    Product Portfolio 
        17.12.3    Demographic Reach and Achievements 
        17.12.4    Mergers and Acquisitions 
        17.12.5    Certifications 
    17.13    Bio-Rad Laboratories, Inc.
        17.13.1    Financial Analysis 
        17.13.2    Product Portfolio 
        17.13.3    Demographic Reach and Achievements 
        17.13.4    Mergers and Acquisitions 
        17.13.5    Certifications 
    17.14    Menarini Silicon Biosystems S.p.A. 
        17.14.1    Financial Analysis 
        17.14.2    Product Portfolio 
        17.14.3    Demographic Reach and Achievements 
        17.14.4    Mergers and Acquisitions 
        17.14.5    Certifications 
    17.15    Epigenomics AG
        17.15.1    Financial Analysis 
        17.15.2    Product Portfolio 
        17.15.3    Demographic Reach and Achievements 
        17.15.4    Mergers and Acquisitions 
        17.15.5    Certifications 
18    Global Liquid Biopsy Market - Distribution Model (Additional Insight) 
    18.1    Overview
    18.2    Potential Distributors
    18.3    Key Parameters for Distribution Partner Assessment
19    Key Opinion Leaders (KOL) Insights (Additional Insight) 
20    Company Competitiveness Analysis (Additional Insight) 

    20.1    Very Small Companies 
    20.2    Small Companies 
    20.3    Mid-Sized Companies 
    20.4    Large Companies 
    20.5    Very Large Companies 
21    Payment Methods (Additional Insight) 
    21.1    Government Funded 
    21.2    Private Insurance 
    21.3    Out-of-Pocket 


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 2269.81 billion in 2023, driven by the rising incidence of cancer cases across the globe.

The market is anticipated to grow at a CAGR of 22% during the forecast period of 2024-2032, likely to reach a market value of USD 13591.48 billion by 2032.

The market demand is driven by the increasing emphasis on preventing recurrence in patients, along with growing investments by influential healthcare companies to adapt latest technologies and develop their own platforms for better patient solutions.

The current market trend involves rising technical advancements in the existing techniques for improved patient care. In February 2023, BCRF researchers developed HDSCA3.0, a third-generation liquid biopsy technology which used five different biomarkers to detect and distinguish rare circulating cells at a high resolution.

It constitutes blood samples and others.

Based on product types, the market is divided into instruments, consumables kits and reagents, software, and services.

It includestherapy selection, treatment monitoring, early cancer screening, and recurrence monitoring, among others.

Major biomarkers include circulating tumor cells (CTCs), circulating nucleic acids, exosomes/ microvesicles and circulating proteins.

Major end users include hospitals and laboratories, specialty clinics, academic and research centres, among others.

Multi-gene-parallel analysis (NGS) and single gene analysis (PCR microarrays) are common technologies available in the market.

Common application areas include cancer, reproductive health, organ transplantation, and infectious diseases testing, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.

Key players involved in the market are ANGLE plc, Oncimmune Holdings PLC, Guardant Health, Myriad Genetics, Inc., Biocept, Inc., Lucence Health Inc., Freenome Holdings, Inc., F.Hoffmann La Roche Ltd., QIAGEN, Illumina, Inc., Thermo Fisher Scientific, Inc., Exact Sciences Corporation, Bio-Rad Laboratories, Inc., Menarini Silicon Biosystems S.p.A., and Epigenomics AG.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER